港股異動 | 諾誠健華-B(9969.HK)反彈逾5% 機構指短期估值具吸引力
格隆匯9月8日丨諾誠健華-B(9969.HK)反彈5.32%,報11.48港元,暫成交2161萬港元,最新總市值148億港元。近期股價持續下跌,昨日大跌10%創下5個月新低。大摩認為,諾誠健華股價近期下滑,短期估值更具吸引力。考慮到產品線近期有多個催化劑,認為目前估值為18億美元的諾誠健華頗具吸引力,予目標估值29億美元,目標價17.5港元,評級增持。招商證券(香港)此前表示,維持基於分類加總估值法的目標價於17.9港元不變,維持買入評級,看好公司新藥審批的催化劑和自主研發管線的拓展。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.